Here are the 10-Q quarterly reports from Braveheart Bio, Inc. (BRVE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRVE filings page.
Braveheart Bio, Inc. (BRVE) reported its first full half-year as a clinical-stage public-ready company, focused on lead cardiac myosin inhibitor BHB-1893 for hypertrophic cardiomyopathy. For the six months ended June 30, 2026, it generated no revenue and recorded a net loss of $29.3 million, driven by $22.0 million in research and development and $8.9 million in general and administrative expenses as Phase 3 preparation ramped up.
As of June 30, 2026, Braveheart held $122.8 million in cash and cash equivalents and total assets of $127.0 million, with liabilities of $9.3 million; operations have been funded primarily through redeemable convertible preferred stock. A subsequent August 7, 2026 IPO raised approximately $404.5 million in net proceeds at $18.00 per share, and management states that existing cash plus IPO proceeds should fund projected operating and capital needs into 2029 as it advances BHB-1893 through global Phase 3 trials in obstructive and non-obstructive HCM.